Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.42 |
| ▸ | PRKCG | P05129 | 3/20 | 0.42 |
| ▸ | PRKCB | P05771 | 3/20 | 0.42 |
| ▸ | PRKCA | P17252 | 3/20 | 0.42 |
| ▸ | PRKCH | P24723 | 3/20 | 0.42 |
| ▸ | PRKCI | P41743 | 3/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.42 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8486597 | 0.92 | CES1 (0.41) | CES2THRBGMNNTP53POLB | |
| SCHEMBL9320634 | 0.85 | HTT (0.45) | CES2THRBGMNNTP53POLB | |
| SCHEMBL226036 | 0.78 | CES2 (0.52) | CES2THRBGMNNTP53POLB | |
| Ether SCHEMBL23576143 | 0.78 | CES2 (0.43) | CES2THRBGMNNTP53POLB | |
| SCHEMBL199047 | 0.76 | THRB (0.57) | CES2THRBGMNNTP53POLB | |
| SCHEMBL198942 | 0.76 | THRB (0.57) | CES2THRBGMNNTP53POLB | |
| SCHEMBL200026 | 0.76 | THRB (0.57) | CES2THRBGMNNTP53POLB | |
| SCHEMBL24370114 | 0.76 | THRB (0.57) | CES2THRBGMNNTP53POLB | |
| SCHEMBL200549 | 0.76 | THRB (0.57) | CES2THRBGMNNTP53POLB | |
| SCHEMBL24362145 | 0.76 | THRB (0.57) | CES2THRBGMNNTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988417-B2 | Process for the preparation of estetrol | CRYSTAL PHARMA, S.A.U. (ES) | 2018-06-05 | — | — | US | disclosed |
| EP-3046928-B1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA SAU (ES) | 2017-02-08 | — | — | EP | disclosed |
| US-20160229885-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-11 | — | — | US | disclosed |
| EP-3046928-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | Crystal Pharma, S.A.U. (ES) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015040051-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2015-03-26 | — | — | WO | disclosed |
| US-6861390-B2 | Derivatives of UK-2A | DOW AGROSCIENCES LLC (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040192924-A1 | Derivatives of uk-2a | CORTEVA AGRISCIENCE LLC | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192924-A1 | Derivatives of uk-2a | TOP2A, RAB2A, UBA2 | CES2 56/4885THRB 2707/4885GMNN 2865/4885 |
| US-20160229885-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | SRD5A2, VKORC1L1, SRD5A1 | CES2 57/4885THRB 1097/4885GMNN 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.